Evidence map›Paper›PMID 41942055›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2026

Targeted and quantitatively modeled biologic delivery via dual-functional probiotic yeast in inflammatory bowel disease.

Anthony G Hazelton, Mairead K Heavey, Jessica R Vlcek, Ameya P Chaudhari, Timothy S Little, Brandon Villanueva-Sanchez, Alaina Parker, Sri Sruthi Potluru, Yuyan Wang, Allaura S Cone and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anthony G HazeltonDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27514, USA; Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, NC 27514, USA.
Mairead K HeaveyDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27514, USA.
Jessica R VlcekDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27514, USA.
Ameya P ChaudhariDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27514, USA.
Timothy S LittleDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27514, USA.
Brandon Villanueva-SanchezDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27514, USA.
Alaina ParkerDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27514, USA; Lampe Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, NC 27514, USA.
Sri Sruthi PotluruDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27514, USA; Lampe Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, NC 27514, USA.
Yuyan WangDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27514, USA.
Allaura S ConeDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, NC 27514, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27514, USA.
Rani S SellersLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27514, USA; Department of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina at Chapel Hill, NC 27514, USA.
Dirk P DittmerDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, NC 27514, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27514, USA.
Janelle C ArthurDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, NC 27514, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27514, USA; Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, NC 27514, USA.
Juliane NguyenDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27514, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27514, USA; Lampe Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, NC 27514, USA. Electronic address: julianen@email.unc.edu.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Vironomics and Biostatistics CoreP01CA019014 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Dirk P Dittmer · 1985 to 2026
$43.8M
PILOT AND FEASIBILITY STUDIESP30DK034987 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ANTHONY BLIKSLAGER · 1985 to 2026
$30.5M
Preclinical CoreP50HD103573 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mark D Shen · 2020 to 2026
$9.7M
UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program-Evaluation SupplementT32GM086330 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KIM L.R. BROUWER, Daniel Gonzalez · 2011 to 2026
$8.5M
INFECTIOUS DISEASE PATHOGENESIS TRAININGT32AI007151 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JULIANO, JONATHAN J · 1985 to 2024
$5.5M
CAROLINA CANCER NANOTECHNOLOGY TRAINING PROGRAM (C-CNTP)T32CA196589 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Gaorav P. Gupta, ALEXANDER V KABANOV · 2015 to 2026
$4.5M
Predoctoral Training in the Pharmacological SciencesT32GM135095 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph Mauro Calabrese, Michael James Emanuele · 2020 to 2026
$3.6M
Targeted Probiotic Yeast for Treating Inflammatory Bowel DiseasesR01DK140954 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Janelle C Arthur, Juliane Nguyen · 2025 to 2026
$1.6M
ImageStreamX Mark IIS10OD017984 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FISHER, NANCY C. · 2015 to 2015
$418k
NCI NIH HHS P01 CA019014NCI NIH HHS P30 CA016086NCI NIH HHS T32 CA196589NIAID NIH HHS P30 AI050410NIAID NIH HHS T32 AI007151NICHD NIH HHS P50 HD103573NIDDK NIH HHS P30 DK034987NIDDK NIH HHS R01 DK140954NIGMS NIH HHS T32 GM086330NIGMS NIH HHS T32 GM135095NIH HHS S10 OD017984
6 · The paper itself

Abstract

Probiotic-based therapies are an emerging class of therapeutic interventions that offer a promising strategy for managing chronic and inflammatory conditions. Here, we engineered a dual-functional probiotic yeast strain, Saccharomyces boulardii, designed to target inflammatory lesions within the gastrointestinal tract and locally deliver protein-based therapeutics. We employed advanced experimental and modeling techniques to characterize the engineered probiotic with preclinical therapeutic efficacy and pharmacokinetic validation in an inflammatory bowel disease (IBD) mouse model. Through these studies, we demonstrate that our engineered yeast enables efficient and localized delivery of biologics with prolonged gastrointestinal retention, driving restorative phenotypic shifts towards measurable improvements in disease outcome. Overall, this work establishes a robust framework for the development of engineered microbial therapeutics, representing an integrative strategy for treating chronic, inflammatory diseases through targeted, localized delivery of bioactive molecules.

Indexed as

Inflammatory Bowel DiseasesProbioticsSaccharomyces boulardiiAnimalsDisease Models, AnimalDrug Delivery SystemsMiceMice, Inbred C57BLEngineered probioticsImmune modulationOral drug deliveryProtein therapeuticsTargeted therapy

Identifiers

PMID41942055
PMCPMC13452468

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.